HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Capricor Therapeutics (NASDAQ:CAPR) and maintained a $40 price target, as stated by analyst Joseph Pantginis.
July 02, 2024 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Capricor Therapeutics and maintained a $40 price target, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $40 price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for investors. It suggests confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100